Generic Vizimpro Availability
Last updated on May 7, 2025.
Vizimpro is a brand name of dacomitinib, approved by the FDA in the following formulation(s):
VIZIMPRO (dacomitinib - tablet;oral)
-
Manufacturer: PFIZER
Approval date: September 27, 2018
Strength(s): 15MG [RLD], 30MG [RLD], 45MG [RLD]
Is there a generic version of Vizimpro available?
No. There is currently no therapeutically equivalent version of Vizimpro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vizimpro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method for treating gefitinib resistant cancer
Patent 10,596,162
Issued: March 24, 2020
Inventor(s): Haber; Daniel A. et al.
Assignee(s): Wyeth LLC (New York, NY); The General Hospital Corporation (Boston, MA)The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
Patent expiration dates:
- February 2, 2026✓
- February 2, 2026
-
Method for treating gefitinib resistant cancer
Patent 10,603,314
Issued: March 31, 2020
Inventor(s): Haber; Daniel A. et al.
Assignee(s): The General Hospital Corporation (Boston, MA); Wyeth LLC (New York, NY)The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
Patent expiration dates:
- February 2, 2026✓
- February 2, 2026
-
4-phenylamino-quinazolin-6-yl-amides
Patent 7,772,243
Issued: August 10, 2010
Inventor(s): Fakhoury; Stephen Alan et al.
Assignee(s): Warner-Lambert Company LLC (Morris Plains, NJ)This invention provides quinazoline compounds of the formula: ##STR00001## wherein: R.sub.1 is halo; R.sub.2 is H or halo; R.sub.3 is a) C.sub.1-C.sub.3 alkyl, optionally substituted by halo; or b) --(CH.sub.2).sub.n-morpholino, --(CH.sub.2).sub.n-piperidine, --(CH.sub.2).sub.n-piperazine, --(CH.sub.2).sub.n---piperazine-N(C.sub.1-C.sub.3 alkyl), --(CH.sub.2).sub.n-pyrrolidine, or --(CH.sub.2).sub.n-imidazole; n is 1 to 4; R.sub.4 is --(CH.sub.2).sub.m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C.sub.1-C.sub.3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH.sub.2, NH(C.sub.1-C.sub.3 alkyl) or N (C.sub.1-C.sub.3 alkyl).sub.2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
Patent expiration dates:
- May 5, 2028✓✓
- May 5, 2028
-
4-phenylamino-quinazolin-6-yl-amides
Patent 8,623,883
Issued: January 7, 2014
Inventor(s): Fakhoury Stephen Alan & Lee Helen Tsenwhei & Reed Jessica Elizabeth & Schlosser Kevin Matthew & Sexton Karen Elaine & Tecle Haile & Winters Roy Thomas
Assignee(s): Warner-Lambert Company LLCThis invention provides quinazoline compounds of the formula:
Patent expiration dates:
- May 5, 2025✓
- May 5, 2025
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 27, 2025 - INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- September 27, 2025 - FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
More about Vizimpro (dacomitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
